Although the two earlier discovered analogs, octreotide and lanreotide, are the most widely used medical therapy for acromegaly, they do not normalize GH and IGF-1 levels in a significant percentage of patients with acromegaly. This evidence concerns the gene IGF1 and acromegaly.